FUJIFILM Corporation, Thermo Fisher Scientific Inc. and Lonza are dominating the Global Induced Pluripotent Stem Cells (Ipscs) Market In 2022

Global Induced Pluripotent Stem Cells (iPSCs) Market is expected to grow with the CAGR of 9.9% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-induced-pluripotent-stem-cells-market

Global Induced pluripotent stem cells (iPSCs) market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global induced pluripotent stem cells (iPSCs) market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance:

  • In March 2021, Applied StemCell. Announced that the company launched three set of TARGATT Master Cell lines products and IPSCs. This new product enhanced the product portfolio over the market.

FUJIFILM Corporation is the dominating player in global induced pluripotent stem cells (iPSCs) market. The other key players existing in the market are Thermo Fisher Scientific Inc., LumaCyte, Horizon Discovery Ltd., Hopstem Biotechnology LLC., Takara Bio Inc., Cell Applications, Inc., Citius Pharmaceuticals, Inc., Lonza., Evotec SE., Fate Therapeutics, Universal Cells Inc. (An Astellas Company), Axol Bioscience Ltd., R & D Systems, Inc., Charles River Laboratories International, Inc., Corning Incorporated, REPROCELL Inc., Applied StemCell., Merck KGaA, GeneCopoeia, Inc. and among others.

Induced Pluripotent Stem Cells (iPSCs) MarketFUJIFILM Corporation

FUJIFILM Corporation headquarter is in Tokyo, Japan and established in 1934. The company is focused on combining technical leadership in cell culture, microbial fermentation, and gene therapies by manufacturing recombinant proteins, viral vaccines, and gene therapies. The company has three business segments healthcare & material healthcare, document, imaging out of which healthcare & material healthcare is focused segment. The company has few product categories Cardiac Cells, Neural Cells, Hematopoietic & Other Cells, Media & Supplements, CIRM IPSC Products, MyCell Custom Services and Accessory Products and CIRM IPSC Products is the focused category for the market.

For instance,

  • In March 2015, FUJIFILM Holdings Corporation acquired Cellular Dynamics International, Inc. which is bio-venture Company. This acquisition helped company in expanding induced pluripotent stem cells supply business in U.S.

The company has wide presence across North America, Europe, Asia-Pacific, South America and Middle East and Africa.

Thermo Fisher Scientific Inc. 

Thermo Fisher Scientific Inc. founded in the year 1956, headquartered in Massachusetts, U.S. The company is focused on making the world healthier, cleaner, and safer by accelerating life science research, solving complex analytical challenges, and improving patient’s therapies and diagnostics. The company has its business segments as life science solutions, analytical instruments, specialty diagnostics, laboratory products, and services and life science solutions is focused segment. The company has many product categories including life sciences, industrial & applied sciences, clinical diagnostics, lab solutions and digital solutions in which life sciences is market focused category.

  • In October 2021, Thermo Fisher Scientific Inc. organized a 5 days stem cell event session from Oct 18-22 virtually. This session aided in discovering incredible insights and advances research with access to scientific presentations from key leaders and prominent researchers all over the world. This thereby enhanced their stem cell research products recognition among customers.

The company has presence across North America, Europe, Asia-Pacific, South America and Middle East and Africa. The company has subsidiaries which includes, Thermo Electron North America LLC (U.S.), Fisher Scientific GmbH (Germany), Fisher Scientific Korea Ltd (Korea), Thermo Fisher Scientific Germany BV & Co KG (Germany), Thermo Fisher Scientific K.K. (Japan) among others.


Lonza founded in the year 1897 headquarter in Basel, Switzerland. The company is focused on enabling treatments that prevent illness, support healthier lifestyles and create a healthy environment. The company has various business segments such as pharma, biotech & nutrition and specialty ingredients in which pharma, biotech & nutrition is focused segment. The company has many product categories which are small molecules, biologics, cell & gene, bioscience, capsule in which cell & gene is the focused segment.

  • In February 2021, Lonza announced that they received a delightful Award from the Ethisphere Institute. This Award was given considering the global standards of business integrity and corporate citizenship set by the company. This improved the profile of company and gained more global audiences.

The company has presence across Lonza Biologics Tuas Pte Ltd (Singapore), Lonza India Private Ltd (India), Lonza Microbial Control Asia Pacific Pte Ltd (Singapore), Lonza Shanghai International Trading Ltd (China) and among others.